Supplementary Materials
The PDF file includes:
- Table S1: Demographic and clinical characteristics of COVID-19 patient cohort
- Table S2: Prevalence of aPL antibodies in serum from COVID-19 patients (n=172) based on the first-available sample.
- Fig S1: Testing for various aPL antibodies according to day of hospitalization.
- Fig S2: Lack of association between aPS/PT antibodies and aPS antibodies in serum from COVID-19 patients.
- Fig S3: A positive aPL antibody test is associated with greater neutrophil activation and worse kidney function.
- Fig S4: Nadir eGFR in COVID-19 patients with or without a prior history of renal disease.
- Fig S5: aPL antibody status as a predictor of oxygenation efficiency.
- Fig S6: aPL antibody status as a predictor of peak troponin and D-dimer.
- Fig S7: D-dimer plasma concentrations in patients with or without obesity.
- Fig S8: Determination of purity of IgG fractions from COVID-19 patients.
- Fig S9: Dipyridamole suppresses IgG-induced NET release.
- Fig S10: IgG from COVID-19 patients does not potentiate thrombin generation in cell-free pooled normal plasma.
- Fig S11: Measurement of citrullinated histone H3 in mouse thrombi.
Other Supplementary Material for this manuscript includes the following:
- Data File S1. NET release measured by myeloperoxidase activity.
- Data File S2. Thrombus length and weight in mice.
- Data File S3. MPO-DNA in mice (stenosis and electrolysis models).
- Data File S4. Thrombus length and weight in stenosis mouse model.
